Trial · NCT07888530
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) after administration [Effectiveness Metrics] | 5 years post infusion | The time from Ranicabtagene Autoleucel Injection infusion to death from any cause. |
| Secondary | Overall response rate (ORR) [Effectiveness Metrics] | 5 years post infusion | Percentage of participants with CR or PR. |
| Secondary | Complete response rate (CRR) [Effectiveness Metrics] | 5 years post infusion | Percentage of participants with CR. |
| Secondary | Duration of remission (DOR) [Effectiveness Metrics] | 5 years post infusion | The time from the first tumor assessment showing CR or PR to the first assessment of disease progression or death from any cause. |
| Secondary | Progression free survival (PFS) [Effectiveness Metrics] | 5 years post infusion | The time from Ranicabtagene Autoleucel Injection infusion to the first assessment of tumor progression or death from any cause. |
| Secondary | Cytokine release syndrome (CRS) [Safety Indicators] | 5 years post infusion | Percentage of participants with CRS. |
| Secondary | Immune effector cell-associated neurotoxicity syndrome (ICANS) [Safety Indicators] | 5 years post infusion | Percentage of participants with ICANS. |
| Secondary | Severe infection [Safety Indicators] | 5 years post infusion | Percentage of participants with severe infection. |
| Secondary | B cell aplasia and hypogammaglobulinemia [Safety Indicators] | 5 years post infusion | Percentage of participants with B cell aplasia and hypogammaglobulinemia. |
| Secondary | Prolonged cytopenia [Safety Indicators] | 5 years post infusion | Percentage of participants with prolonged cytopenia. |
| Secondary | Abnormal laboratory results [Safety Indicators] | 5 years post infusion | Percentage of participants with abnormal laboratory results. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07888530/registered